EGFR and metastatic colorectal cancer: The best studied reactions are immediate anaphylactic reactions following first-time intravenous administration of cetuximab, a chimeric mouse-human monoclonal IgG antibody against the epidermal growth factor receptor (EGFR), which is applied in patients with metastatic colorectal cancer (29).